Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of “Buy” by Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has earned an average rating of “Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have covered the stock in the last year is $21.00.

ARTV has been the subject of a number of recent research reports. HC Wainwright initiated coverage on shares of Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a “buy” rating and a $20.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th.

Artiva Biotherapeutics Stock Performance

ARTV opened at $10.67 on Monday. Artiva Biotherapeutics has a 12-month low of $9.68 and a 12-month high of $17.31. The stock’s fifty day moving average price is $11.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, equities analysts expect that Artiva Biotherapeutics will post -4.68 EPS for the current year.

Institutional Trading of Artiva Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new position in Artiva Biotherapeutics during the 3rd quarter worth $166,000. Franklin Resources Inc. acquired a new stake in Artiva Biotherapeutics in the third quarter worth about $7,435,000. Barclays PLC purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $304,000. Geode Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at about $4,774,000. Finally, Wellington Management Group LLP purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $2,912,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.